RxDoctor Payments Data

Andrea Sanchez, MD

Internal Medicine · Mission Hills, CANPI 1467689638

Payments from drug & device makers

$324in general payments, 2019–2025

Across 21 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$64
  • E.r. Squibb & Sons, L.L.C.$62
  • Novo Nordisk$57
  • Teva Pharmaceuticals USA, Inc.$41
  • Merck$34
  • Optinose US, Inc.$24
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$324 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$29,759
Medicare patients
122
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$223,109
OfevNintedanib Esylate15$183,509
EliquisApixaban83$94,241
TrulicityDulaglutide72$85,750
JardianceEmpagliflozin36$41,842
JanuviaSitagliptin Phosphate17$24,098
XareltoRivaroxaban16$21,642
MounjaroTirzepatide17$19,698
EntrestoSacubitril/Valsartan24$14,652
MyrbetriqMirabegron13$13,602
Metformin Hcl262$7,236
Atorvastatin Calcium602$6,380
Losartan Potassium410$6,267
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,131
Humalog Kwikpen U-100Insulin Lispro14$4,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$57$223,109164 claims
PfizerEliquis$16$94,24183 claims
MerckJanuvia$34$24,09817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →